Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 631 to 645 of 2854 results for process

  1. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Gantenerumab for treating early Alzheimer's disease [TSID10668]

    Awaiting development Reference number: GID-TA11072 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Bimekizumab for treating ankylosing spondylitis [ID4011]

    Awaiting development Reference number: GID-TA11150 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]

    Awaiting development Reference number: GID-TA10519 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Atrasentan for treating primary IgA nephropathy [ID6558]

    Awaiting development Reference number: GID-TA11756 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Sibeprenlimab for treating IgA nephropathy [ID6604]

    Awaiting development Reference number: GID-TA11668 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Sabizabulin for treating COVID-19 [TSID11814]

    Awaiting development Reference number: GID-TA11226 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Vilobelimab for treating COVID-19 [TSID11815]

    Awaiting development Reference number: GID-TA11227 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]

    Awaiting development Reference number: GID-TA11841 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Treprostinil diethanolamine for treating pulmonary arterial hypertension [ID6366]

    Awaiting development Reference number: GID-TA11123 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]

    Awaiting development Reference number: GID-TA11532 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040]

    Awaiting development Reference number: GID-TA11591 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Efzimfotase alfa for treating hypophosphatasia [ID6633]

    Awaiting development Reference number: GID-TA11838 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development